“Glucagon-like Peptide Receptor Agonists (GLP-1 receptor agonists): A Powerful Addition to Foundational Therapy Kidney Care in Patients with Type 2 Diabetes Mellitus” (2024) Canadian Diabetes & Endocrinology Today, 2(3), pp. 33–37. doi:10.58931/cdet.2024.2333.